NEW YORK (GenomeWeb) – Luminex today announced that its xTAG universal tag technology has been selected for use in Assurex Health's GeneSight neuropsychiatric pharmacogenomics tests.

Gene Sight compares patients' DNA signatures with known pharmacology in order to predict how they might react to medicines used to treat depression, post-traumatic stress disorder, anxiety, bipolar disease, schizophrenia, and other behavioral health conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.